Your browser doesn't support javascript.
loading
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.
Fernandes Neto, João M; Nadal, Ernest; Bosdriesz, Evert; Ooft, Salo N; Farre, Lourdes; McLean, Chelsea; Klarenbeek, Sjoerd; Jurgens, Anouk; Hagen, Hannes; Wang, Liqin; Felip, Enriqueta; Martinez-Marti, Alex; Vidal, August; Voest, Emile; Wessels, Lodewyk F A; van Tellingen, Olaf; Villanueva, Alberto; Bernards, René.
Afiliação
  • Fernandes Neto JM; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Nadal E; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
  • Bosdriesz E; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Ooft SN; Department of Computer Science, Faculty of Science, Vrije Universiteit, Amsterdam, The Netherlands.
  • Farre L; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
  • McLean C; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
  • Klarenbeek S; Institute Gonçalo Moniz, Fundaçao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brasil.
  • Jurgens A; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
  • Hagen H; Experimental Animal Pathology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
  • Wang L; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Felip E; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Martinez-Marti A; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Vidal A; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Voest E; Autonomous University of Barcelona (UAB), Barcelona, Spain.
  • Wessels LFA; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • van Tellingen O; Autonomous University of Barcelona (UAB), Barcelona, Spain.
  • Villanueva A; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
  • Bernards R; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
Nat Commun ; 11(1): 3157, 2020 06 22.
Article em En | MEDLINE | ID: mdl-32572029
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Inibidores de Proteínas Quinases / Receptores ErbB Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Inibidores de Proteínas Quinases / Receptores ErbB Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda